IP Library › Granted Patent US 10,053,496
Granted Patent B2
US 10,053,496 · App. 15/660,572 · Granted Aug 21, 2018

Compositions and methods for exosome targeted expression

Inventors: Vincent Craig Bond (Stone Mountain, GA); Michael Powell (Douglasville, GA); Ming Bo Huang (Atlanta, GA); Syed Ali (New Iberia, LA)
Assignee: MOREHOUSE SCHOOL OF MEDICINE
C07K14/005A61K9/127A61K38/162A61K39/39A61K45/06C07K14/163C12P21/02G01N33/543G01N33/566A61K38/00A61K2039/55555C07K2319/055C07K2319/50C07K2319/60C12N15/00C12N2740/16322
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,053,496
App. No.
15/660,572
Granted
Aug 21, 2018
Kind
B2
Abstract

The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.

Claims (17)

1. A Nef-fusion protein, produced by

culturing cells that produce exosomes containing said Nef-fusion protein;

isolating exosomes from said cells; and

purifying said Nef-fusion protein from isolated exosomes,

wherein said Nef-fusion protein comprises a Nef-derived peptide fused to a protein of interest and wherein said Nef-derived peptide consists of one of either SEQ ID NO:3, or 4.

2. The Nef-fusion protein of claim 1 , wherein said Nef-derived peptide consists of SEQ ID NO:3.

3. The Nef-fusion protein of claim 1 , wherein said Nef-derived peptide consists of SEQ ID NO:4.

4. The Nef-fusion protein of claim 1 , wherein said protein of interest is an immunogenic protein.

5. The Nef-fusion protein of claim 4 , wherein said immunogenic protein comprises at least a portion of a tumor antigen.

6. The Nef-fusion protein of claim 1 , further comprising one or more functional domains.

7. The Nef-fusion protein of claim 6 , wherein the one or more functional domains are selected from the group consisting of affinity tags, protease cleavage sites, targeting domains, reporters and enzymes.

8. The Nef-fusion protein of claim 6 , wherein the one or more functional domains comprise one or more affinity tags selected from the group consisting of glutathione S-transferase (GST), histidine tag, maltose binding protein (MBP), protein A, thioredoxin, ubiquitin, biotin, calmodulin binding peptide (CBP), streptavidin tag, FLAG octapeptide tag, hemaglutinin A (HA) tag, and myc tag.

9. The Nef-fusion protein of claim 6 , wherein the one or more functional domains comprise one or more protease cleavage sites selected from the group consisting of cleavage sites sensitive to thrombin, furin, factor Xa, metalloproteases, enterokinases, or cathepsin.

10. The Nef-fusion protein of claim 6 , wherein the one or more functional domains comprise one or more targeting domains selected from the group consisting of antibodies, antibody derivatives, peptide ligands, receptor ligands, receptor fragments and hormones.

11. A pharmaceutical composition, comprising:

the Nef-fusion protein of claim 1 ; and

a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2017
From: BOND, VINCENT C.; POWELL, MICHAEL; HUANG, MING BO; ALI, SYED
To: MOREHOUSE SCHOOL OF MEDICINE
Reel/Frame 043738/0204 →
Continuity (2)
Continuation 13327244 · Dec 15, 2011
Related Publication 20170369533A1 · Dec 28, 2017